RBC Capital Maintains Outperform on Cytokinetics, Lowers Price Target to $117

Benzinga · 07/07 16:11
RBC Capital analyst Leonid Timashev maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and lowers the price target from $119 to $117.